The committee will discuss new drug application (NDA) 22-268, artemether 20 mg/lumefantrine 120mg, sponsored by Novartis Pharmaceuticals Corporation, for the proposed indication of treatment of acute, uncomplicated malaria infection due to Plasmodium falciparum or mixed infections including P. falciparum.
